Nice!

Good morning everyone!

$BLEG

Good morning hotdawg / everyone!

Watching and waiting!

$RSPI

Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences

July 8, 2024

TuHURA has an exclusive right to negotiate to acquire Kineta’s KVA12123 Immuno-Oncology Drug Program

Kineta will receive a $5 million Nonrefundable Payment from TuHURA

KVA12123 is currently in a Phase 1/Phase 2 Clinical Study in the United States

SEATTLE, July 08, 2024 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into an exclusivity and right of first offer agreement (the “Agreement”) with TuHURA Biosciences, Inc. (“TuHURA”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Pursuant to the Agreement, among other things, Kineta has granted TuHURA an exclusive right to acquire Kineta’s worldwide patents, patent rights, patent applications, product and development program assets, technical and business information, and other rights and assets associated with and derived from its development program related to KVA12123, the Company’s VISTA blocking immunotherapy. This exclusive right shall continue through the first to occur of (a) the execution of any definitive agreement with respect to a potential transaction by TuHURA or one or more of its affiliates and (b) 11:59 PM Eastern Time on October 1, 2024, subject to extension. In consideration for Kineta’s compliance with its obligations set forth in the Agreement, TuHURA will pay Kineta a $5 million nonrefundable payment.

KVA12123 is a novel VISTA blocking monoclonal antibody being evaluated in a Phase 1/Phase 2 clinical trial for patients with advanced solid tumors. The study includes a monotherapy arm with KVA12123 alone, and a combination arm utilizing KVA12123 together with Merck’s anti-PD1 therapy, KEYTRUDA (pembrolizumab). Initial results from this study were reported in April this year at the American Association of Cancer Research. To date, the drug has been well tolerated with no dose limiting toxicities and no cytokine release syndrome. Additional data is expected to be released in the fourth quarter of 2024.

“TuHURA Biosciences is well positioned to advance KVA12123,” said Craig W. Philips, President of Kineta. “TuHURA is a Phase 3 registration stage immuno-oncology company with expertise and deep experience in the field. We believe they will make an excellent partner for this program and in advancing this novel drug program which could provide an important new treatment option for cancer patients.”

About Kineta
Kineta (Nasdaq: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. The company’s immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27. For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on X (formerly Twitter) and LinkedIn.

KVA12123, through the combination of unique epitope binding and an optimized IgG1 Fc region, has demonstrated strong tumor growth inhibition as both a monotherapy or in combination with other checkpoint inhibitors in preclinical models. KVA12123 provides a novel approach to address immune suppression in the TME with a mechanism of action that is differentiated and complementary with T cell focused therapies. KVA12123 may be an effective immunotherapy for many types of cancer including non-small cell lung (NSCLC), colorectal, renal cell carcinoma, head and neck, and ovarian cancer.

In February 2024, Kineta announced a significant corporate restructuring to substantially reduce expenses and preserve cash. The restructuring included a significant workforce reduction and the suspension of enrollment of new patients in its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. Patients currently enrolled in the trial will be permitted to continue to participate. The Company announced the restructuring as a result of certain investors indicating that they would not fulfill their April 2024 funding obligation in the previously disclosed private placement financing. In connection with the restructuring, the Company announced that it is exploring strategic alternatives to maximize stockholder value.

https://forextv.com/top-news/kineta-announces-exclusivity-and-right-of-first-offer-agreement-for-its-vista-blocking-antibody-with-tuhura-biosciences/

$KA

Thanks BillyRaven and agree!

Nikola Wholesales 72 Hydrogen Fuel Cell Trucks For North American Customers In Q2 2024, Exceeds Sales Guidance

Published July 2, 2024

PHOENIX – July 2, 2024 – For Q2 2024, Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, via the HYLA brand, wholesaled 72 Class 8 Nikola hydrogen fuel cell trucks, above the high end of truck sales guidance of 60 units.

For the first half of 2024, Nikola wholesaled 112 hydrogen fuel cell trucks.

“We have maintained our 2024 momentum with solid wholesale numbers, new customers such as Walmart Canada, and repeat customers like 4GEN and IMC, purchasing vehicles through our dealer network,” said Nikola CEO Steve Girsky. “We are firmly on the field and are continuing to secure our first-mover advantage in zero-emissions Class 8 trucks in North America, as well as with our HYLA hydrogen refueling solutions.”

All Nikola trucks are assembled in Coolidge, Ariz.

NOTE: Nikola has not completed its quarterly review process or the preparation of its financial statements for the second quarter ended June 30, 2024.

ABOUT NIKOLA CORPORATION
Nikola Corporation’s mission is clear: pioneering solutions for a zero-emissions world. As an integrated truck and energy company, Nikola is transforming commercial transportation, with our Class 8 vehicles, including battery-electric and hydrogen fuel cell electric trucks, and our energy brand, HYLA, driving the advancement of the complete hydrogen refueling ecosystem.

Nikola headquarters is based in Phoenix, Arizona with a manufacturing facility in Coolidge, Arizona.

Experience our journey to achieve your sustainability goals at nikolamotor.com or engage with us on social media via Facebook @nikolamotorcompany, Instagram @nikolamotorcompany, YouTube @nikolamotorcompany, LinkedIn @nikolamotorcompany or X/Twitter @nikolamotor.

MEDIA INQUIRIES
press@nikolamotor.com

https://www.nikolamotor.com/nikola-wholesales-72-hydrogen-fuel-cell-trucks-for-north-american-customers-in-q2-2024-exceeds-sales-guidance

$NKLA

Agree 💯 1jas!
Watching and waiting!

GLTA 🍀 $BLEG

Good morning. Great start. Looking good PB!

GLTA 🍀 $EMGE

Thanks SecondLife! You too, buddy 😃 and agree especially for a Friday!

Great day so far!! Looking good 💹

$RSPI

Yeah it's better to be honest about OS/AS because it's important information.
(I like it when companies update OS/AS regularly.)

GLTA $BLEG

Yeah... and some who listened missed out the rise in SP.
But... We've been warned... That's why you got to have your own strategy!
(RSI is not always accurate!)

$RSPI

Think someone is looking too much at RSI charts 😃 and not the RSPI chart 💹

$RSPI

Looks like it! 😃 Boom! 💹

Very nice site!

$BLEG

If all goes 'ok' then 'anything' is possible.
All depends on great progress IMHO.

$RSPI

Good morning sharky / BLEG-ers! Nice news!

==============

Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing
June 27 2024 - 8:30AM

Melbourne, FL -- June 27, 2024 -- InvestorsHub NewsWire -- Branded Legacy, Inc. (OTC.PK: BLEG), a leading manufacturer of wellness products, is thrilled to announce a new strategic partnership with Hemp Emu, a renowned provider of premium CBD products. This collaboration will enable Branded Legacy to manufacture Hemp Emu’s extensive range of high-quality CBD products, including creams, roll-ons, gummies, and tinctures, at its state-of-the-art facilities in Melbourne, Florida.

Key Details of the Partnership:

Enhanced
Production: Branded Legacy will leverage its advanced manufacturing techniques to boost the production efficiency of Hemp Emu’s CBD products.

Faster
Delivery: This partnership aims to ensure faster delivery times to customers across the United States, meeting the increasing demand for Hemp Emu’s popular products.

Quality
Assurance: Both companies are committed to maintaining the highest standards of quality and effectiveness in their product offerings.

Hemp Emu, known for its pure CBD isolate products and innovative use of emu oil for enhanced transdermal absorption, is excited about the opportunities this partnership presents. Michael Wainer, COO at Hemp Emu, commented, "We are thrilled to partner with Branded Legacy, a company that shares our commitment to excellence and innovation in the CBD industry. This partnership will streamline our manufacturing process, improve supply chain efficiency, and ultimately provide our customers with even better products and services."

Branded Legacy, renowned for its cutting-edge production facilities and dedication to quality, is equally enthusiastic about this collaboration. Dave Oswald, CEO of Branded Legacy, stated, "We are honored to collaborate with Hemp Emu, a brand that has built a strong reputation for delivering exceptional CBD products. Together, we will ensure these products continue to meet the highest standards of quality and effectiveness."

In partnership with Branded Legacy, Hemp Emu customers can look forward to the same great products they have come to love, now manufactured with even greater precision and care. Both companies remain dedicated to providing natural, effective, and safe CBD solutions for a variety of health and wellness needs.

For more information about Hemp Emu and its products, please visit Hemp Emu's website.

About Hemp Emu:
Hemp Emu is a leading provider of CBD products designed to promote health and wellness. With a commitment to quality, transparency, and customer satisfaction, Hemp Emu offers a wide range of products, including CBD creams, roll-ons, gummies, and tinctures.

About Branded Legacy:
Branded Legacy is a reputable manufacturer known for its cutting-edge production facilities and high quality standards. Specializing in the manufacturing of CBD and other wellness products, Branded Legacy is dedicated to innovation and excellence in the industry.

For more information, please contact:
Joe Holladay
Branded Legacy
Phone: 321-345-3565
Email: info@brandedlegacy.com
Website: https://brandedlegacy.com/

https://ih.advfn.com/stock-market/USOTC/branded-legacy-pk-BLEG/stock-news/94111840/branded-legacy-inc-and-hemp-emu-announce-strateg

$BLEG

Big move!

=============

Why Is Assure (IONM) Stock Up 191% Today?
Story by William White
27 June 2024

Assure (NASDAQ:IONM) stock is soaring higher on Thursday after the neuromonitoring surgical support services company withdrew a share offering.

Assure notes that it no longer plans to move forward with a proposed stock offering that was announced on May 3. This offering was tied to the company’s plan to merge with Danam Health.

https://www.msn.com/en-us/money/savingandinvesting/why-is-assure-ionm-stock-up-191-today/ar-BB1oZQ33

$IONM

Looking forward to your posts/insight DD-dempsey!

Nice strong day!!
Chart looks good 💹

$RSPI

I like green % 💹

Absolutly SecondLife!

Agree!

Good morning everyone ☕️

GLTA $TKMO

Good morning elks / everyone!

Agree!

Yep watching and waiting for filings and more news!

GLTA $RSPI

Great start georgie18!



$TKMO

Good morning everyone!

$RSPI

Good morning 0.0012!

$TKMO

Good morning hotdawg / everyone!

Texas is the largest host of Fortune 500 companies.

1. Texas / 49 (2021) / 55 (2024)
2. Califo / 53 (2021) / 53 (2024)
3. N York / 53 (2021) / 50 (2024)

=============================

The 100 Largest Companies In Texas For 2024
Mar. 19, 2024

If you live in Texas and you’re looking for a job, you have come to the right place.

Because, sure, you can google things like ‘biggest companies in Texas’ and get a fairly long list of companies with a lot of employees, or perhaps that have the biggest names — but here, we bring you the companies with the most current employees that are actually headquartered in Texas.

Below, we’ll give you a complete list of Texas’s 100 largest companies, but first, here’s a look at the top 10:

1. AT&T (Jobs)
2. Tech Mahindra (Jobs)
3. American Airlines (Jobs)
4. Denali (Jobs)
5. Tenet Healthcare (Jobs)
6. Whole Foods Market (Jobs)
7. Ge Packaged Power Inc (Jobs)
8. Affiliated Computer Services (Jobs)
9. National Lending Corporation (Jobs)
10. Exxon Mobil (Jobs)

AT&T comes in at the top, with more current employees than any other company in the state. We’ll get to specifics in a moment; first, here’s a look at our methodology.

How we identified the biggest companies in Texas
Here at Zippia we have developed a database of over 250,000 companies that spans the entire country.
For this report, we looked at the companies headquartered in Texas with at least 100 employees. That left us with 3,000 companies.
We then ranked each company from most to least current employees to determine the biggest companies in Texas.
As it turns out, AT&T looks to the be the biggest company in Texas clocking in with 230,000 employees.
Now, check out how the 100 biggest companies in Texas ranked.

Detailed List Of The 100 Biggest Companies In Texas:
1 AT&T, Dallas, 230,000 Jobs
2 Tech Mahindra, Richardson, 141,193 Jobs
3 American Airlines, Fort Worth, 133,700 Jobs
4 Denali, Houston, 111,301 Jobs
5 Tenet Healthcare, Dallas, 102,000 Jobs
6 Whole Foods Market, Austin, 91,000 Jobs
7 Ge Packaged Power Inc, Houston, 82,000 Jobs
8 Affiliated Computer Services, Dallas, 75,000 Jobs
9 National Lending Corporation, Houston, 72,000 Jobs
10 Exxon Mobil, Irving, 72,000 Jobs
11 Sysco, Houston, 69,000 Jobs
12 Air Liquide, Houston, 66,000 Jobs
13 Baker Hughes, a GE, Houston, 60,000 Jobs
14 JCPenney, Plano, 60,000 Jobs
15 Halliburton, Houston, 55,000 Jobs
16 Baker Hughes, Houston, 55,000 Jobs
17 Cemex, Houston, 50,000 Jobs
18 Baylor Scott & White Health, Dallas, 49,000 Jobs
19 BNSF Railway, Fort Worth, 41,000 Jobs
20 McDermott International, Houston, 40,000 Jobs
21 Kimberly-Clark, Irving, 40,000 Jobs
22 CROSSMARK, Plano, 40,000 Jobs
23 Triad Hospitals, Plano, 38,000 Jobs
24 LSG Sky Chefs, Irving, 35,679 Jobs
25 IYG Holding Company, Dallas, 34,000 Jobs
26 USAA, San Antonio, 32,896 Jobs
27 Driveline Retail Merchandising, Coppell, 31,000 Jobs
28 Encompass Services Corporation, Houston, 31,000 Jobs
29 Fertitta Group Inc, Houston, 30,544 Jobs
30 Sasol Chemicals (USA) LLC, Houston, 30,100 Jobs
31 AccentCare, Dallas, 30,000 Jobs
32 Arrow Value Recovery, Austin, 30,000 Jobs
33 Aimbridge Hospitality, Plano, 30,000 Jobs
34 Texas Instruments, Dallas, 29,888 Jobs
35 KBR, Houston, 28,000 Jobs
36 OI Analytical, College Station, 26,500 Jobs
37 Cooper Industries, Houston, 26,000 Jobs
38 Stonebridge Life Insurance Company, Plano, 25,000 Jobs
39 Medco Health Solutions, Inc., Irving, 24,000 Jobs
40 Cameron International, Houston, 23,412 Jobs
41 Perot Systems, Plano, 23,100 Jobs
42 Texas Health Resources, Arlington, 22,005 Jobs
43 Keurig Dr Pepper, Plano, 21,000 Jobs
44 Old HB Inc, Irving, 21,000 Jobs
45 Alcon, Fort Worth, 20,001 Jobs
46 Tenaris, Houston, 19,399 Jobs
47 Dairy.com, Frisco, 19,307 Jobs
48 Arrow Systems Integration, Irving, 19,300 Jobs
49 EqualizeRCM, Austin, 19,000 Jobs
50 Pier 1, Fort Worth, 18,000 Jobs
51 Brenntag Southwest, Houston, 17,500 Jobs
52 Freescale Semiconductor Holdings V Inc, Austin, 16,800 Jobs
53 Physicans At Sugar Creek, Sugar Land, 16,505 Jobs
54 Randalls Food Market, Houston, 16,000 Jobs
55 Waste Connections, Spring, 16,000 Jobs
56 SourceHOV, Coppell, 16,000 Jobs
57 LSRI Holdings, Inc., Houston, 16,000 Jobs
58 Texas Energy Future Holdings Limited Partnership, Fort Worth, 15,750 Jobs
59 Trinity Industries, Dallas, 15,605 Jobs
60 Saltgrass Steak House, Houston, 15,000 Jobs
61 Nabors Drilling USA, LP, Houston, 15,000 Jobs
62 Washington Mutual Card Services, Austin, 15,000 Jobs
63 McLane, Temple, 15,000 Jobs
64 Nabors Industries, Houston, 15,000 Jobs
65 Phillips 66, Houston, 14,600 Jobs
66 Andeavor, San Antonio, 14,300 Jobs
67 Lyondell Chemical Company, Houston, 14,000 Jobs
68 Elbit Systems of America, Fort Worth, 13,895 Jobs
69 Adcorp Sign Systems, Conroe, 13,612 Jobs
70 Neiman Marcus Group, Dallas, 13,500 Jobs
71 Comfort Systems USA, Houston, 13,200 Jobs
72 Chili’s Grill & Bar, Dallas, 13,000 Jobs
73 Zale Corporation, Irving, 12,500 Jobs
74 CST Brands, San Antonio, 12,380 Jobs
75 TRT Holdings, Dallas, 12,000 Jobs
76 Concentra, Addison, 12,000 Jobs
77 ISCAR, Arlington, 12,000 Jobs
78 Energy Transfer, Dallas, 11,421 Jobs
79 Nexstar Media Group, Irving, 11,086 Jobs
80 Dresser-Rand Group, Houston, 11,001 Jobs
81 Enbridge, Houston, 11,001 Jobs
82 CHICAGO BRIDGE & IRON CO, The Woodlands, 11,000 Jobs
83 American Income Life Insurance, McKinney, 11,000 Jobs
84 USPI Group Holdings Inc, Addison, 11,000 Jobs
85 Ponderosa Steakhouse, Plano, 10,525 Jobs
86 Temple-Inland, Austin, 10,500 Jobs
87 ConocoPhillips, Houston, 10,400 Jobs
88 Bell Flight, Fort Worth, 10,200 Jobs
89 Valero Energy, San Antonio, 10,015 Jobs
90 Elan Financial Services, Irving, 10,002 Jobs
91 Ingram Park Medical Group, San Antonio, 10,002 Jobs
92 Fusion Geophysical, Houston, 10,002 Jobs
93 Volunteer Services Council For Denton State Supported Living Center, Austin, 10,001 Jobs
94 Men’s Wearhouse, Houston, 10,001 Jobs
95 Epic Health Services, Dallas, 10,001 Jobs
96 CHI St. Luke’s Health, Houston, 10,001 Jobs
97 Continental Airlines, Houston, 10,001 Jobs
98 Iscar Metals, Arlington, 10,000 Jobs
99 Meador Staffing, Pasadena, 10,000 Jobs
100 GAS Unlimited, Sugar Land, 10,000 Jobs

https://www.zippia.com/advice/largest-companies-in-texas/

$BLEG

Agree dinogreeves

* 0.001 (25,00%) 😁

$TKMO

Agree waterpro42!

Agree 🥳. Another strong day and close! 0.0011 (+37.50%)

Have a great weekend TKMO-ers!

$TKMO 🚀

Bought some more today!

$BLEG

About ResolutionRx
ResolutionRx Ltd (Australian Company Number a/k/a ACN 664 925 651) was formed in Australia on 11th January 2023 by RespireRx as an unlisted public company for the purpose of discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including sleep related breathing disorders such as obstructive sleep apnoea (“OSA”).

Strategy
ResolutionRx has chosen to use alternative, innovative methods in order to bring drugs to market faster, cheaper and with less risk. One of these methods is to circumvent the very costly and time consuming drug discovery stage by repurposing known drugs for new uses and re-evaluating known drug development programs that have not been successful and are no longer the focus of other, larger pharmaceutical companies. Frequently, important information regarding drugs, neuronal substrates and mechanisms of drug action that is publicly available can guide a drug acquisition program to acquire overlooked drug programs or determine new uses for existing drugs. We believe that considerable value still exists in many already approved drugs that are off their original patents and terminated research programs if proper analyses are made concerning the reasons for their demise. In particular, we believe that value can be found using the concepts of “rediscovery” and “repurposing.

RePurposing - a process whereby value can be found by (a) determining that an identified neuronal substrate is involved in an undiscovered or little know therapeutic area; (b) demonstrating that acquired drugs targeting that neuronal substrate demonstrate efficacy in predictive animal tests; and (c) acquire drugs that have successfully demonstrated safety in Phase 1 clinical studies and target engagement of the desired neuronal substrate. We have identified and describe these processes as Repurposing and Rediscovery.

ReDiscovery - a process whereby value can be found by (a) mining published literature to identify a validated neuronal target; (b) identifying and acquiring drug(s) with appropriate mechanisms of action on the identified target; (c) acquiring drug(s) that have strong preclinical data demonstrating efficacy and safety and at least be ready to begin IND enabling studies in preparation for clinical trials; or (d) clinical studies demonstrating safety (Phase 1) and optimally efficacy (Phase 2).

Our first step to implement this strategy is having licensed the exclusive rights to what is now the ResolutionRx dronabinol development program, including patents granted and pending and proprietary confidential information via sublicense and license agreements with RespireRx.

Foundations of ResolutionRx

Development Strategy for OSA
In order to reduce risk, cost, and achieve R&D efficiencies we are repurposing and developing dronabinol for the treatment of OSA, according to Australian TGA and U.S. FDA and other foreign accepted regulatory pathways to market and sell a new drug.

Clinical Validation
Two Phase 2 clinical trials have been completed demonstrating the ability of dronabinol to significantly reduce the symptoms and quantitative measures of obstructive sleep apnea ("OSA"), a sleep related breathing disorder that afflicts an estimated 90 million people in the US, Australia, Germany, and UK combined.

Intellectual Property
Issued and pending patents claiming compositions and methods for treating sleep related breathing disorders, such as OSA and other conditions, as well as novel dosage and controlled release compositions applicable to dronabinol and other drug candidates.

Defined Regulatory Route to Commercialization
505(b)(2) NDA in US and similar filings in other countries creates expedited path to market by allowing publicly available safety data.

Business Plan
Business plan, financial projections and independent evaluation in place.

https://www.resolutionrx.com.au/company-overview

$RSPI

If a stock goes to let say a 'dollar' then you don't need much shares.
I bought T*SNP (in trips) as a lotto play it became H*MBL and that stock went from trips (0.00001 - 0.0001) to 1 - 2 dollars (on a lot of FOMO) in a couple of months without a RS.

If you still have a few million or even 100,000, 200,000, 300,000, 400,000 or 500,000 shares... well that's still a lot of money if it goes to dollars, but that's IF of course.

$RSPI

You are very welcome here Dj56 and I like your 'curiosity/insight' etc. I think you learn a lot by doing that and in a short amount of time. And you probably/definitely know more now than I did in my first months/years when I just started trading 😃 LOL.